Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0731 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MK0731 | DRUG | - |
Inclusion Criteria: * Patients who are at least 18 years of age with recurrent or non-responsive solid tumors, or cancers for whom standard therapy does not exist. Part of the study includes only patients who have taxane-resistant cancers. Exclusion Criteria: * Patients who have had treatment wit...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
MK0731 is an investigational small molecule being studied for the treatment of cancer. It is in Phase 1 clinical development, with a completed trial in patients with advanced solid tumors. The drug is not approved and remains under investigation for its safety and efficacy in oncology.
MK0731 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical research to evaluate the drug's potential in treating cancer.
MK0731 is in Phase 1 clinical development. A Phase 1 study of the drug in patients with advanced solid tumors has been completed. The drug is investigational and has not been approved by regulatory authorities for any use.
MK0731 has one completed clinical trial, identified as NCT00104364, titled 'A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED)'. This Phase 1 study enrolled 30 participants with cancer, with a minimum age of 18 years.
MK0731 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A completed trial has evaluated its use in advanced solid tumors, but the drug has not received regulatory approval for any indication.